Silverbacktx.com Website Review

Developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once Sometimes, the answer becomes clear when you look at the problem from a new perspective. Silverback Thera*eutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now. Our team brings together diverse perspectives and de*p experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. At the core of our pipeline is our proprietary ImmunoTAC technology, which is designed to create potent thera*eutic molecules that can be systemically administered to patients but that act only at the sites of disease, sparing healthy tissues from Armed with this technology, we believe that it is finally possible to overcome some of the biggest barriers to creating effective and enduring treatments for cancer, fibrosis, infectious diseases, and other devastating conditions. Silverback is based in the vibrant South Lake Union neighborhood in Seattle, Washington, where our multi-disciplinary team is rapidly advancing our lead programs toward clinical trials in multiple indications. Since our founding in 2016, we have raised $47.5 million in venture capital from OrbiMed, Celgene Corporation, and Alexandria Venture Investments. Co-Founder, President, Chief Executive Officer, and Chairman Peter Thompson, M.D., is co-founder, president, and CEO of Silverback Thera*eutics. He also serves as chairman of the board of directors… Valerie Odegard, Ph.D., is the chief scientific officer of Silverback Thera*eutics. She brings nearly 20 years of research… Patricia Leith, Pharm.D., is Silverback’s vice president of program management and operations. She has over 20 years of experience in… Peter Baum, Ph.D., is Silverback’s vice president of immunology. Dr. Baum has nearly 30 years of research and development experience in the